Today: 21 May 2026
VeriSilicon (688521.SH) stock set for Monday test after 2025 forecast flags AI-order jump
25 January 2026
1 min read

VeriSilicon (688521.SH) stock set for Monday test after 2025 forecast flags AI-order jump

Shanghai, Jan 25, 2026, 10:23 CST — Market closed

VeriSilicon Microelectronics (Shanghai) Co., Ltd. projects a roughly 36% jump in revenue for 2025, with its annual loss shrinking. The boost comes as AI computing orders climb and its backlog expands toward year-end.

The Shanghai-listed chip design and IP licensing company projects 2025 revenue around 3.15 billion yuan, marking a 35.81% increase from last year, according to its annual forecast dated Jan. 24. It expects a net loss to shareholders of about 449 million yuan, an improvement from the 601 million yuan loss in 2024. New orders in 2025 are estimated at roughly 5.96 billion yuan, with AI-computing related orders making up more than 73%. Orders on hand are set to climb to approximately 5.08 billion yuan by the end of 2025.

The update arrives as A-share investors shift focus from momentum trading to scrutinizing earnings, putting chip stocks under pressure to prove the AI buildout is moving into contracted projects—and, ultimately, profitability.

Orders on hand offer a rough gauge of future revenue since they reflect signed deals not yet recorded. But they can be misleading too: projects sometimes slip when customers delay tape-out or postpone mass production.

VeriSilicon’s Class A shares ended Friday at 206.60 yuan, up 1.35%. They’ll face their first pricing test when Shanghai markets reopen Monday.

The company’s forecast remained largely unchanged. It said revenue is outpacing costs, yet it continues to invest heavily in research and development, calling it the heart of its business model.

But traders hoping for a clean rerating should note a key caveat: the numbers are preliminary and unaudited, and the company remains unprofitable. A dip in order conversion or pricing pressure as customers hunt for cheaper design options could quickly unravel the narrative.

Monday’s open (Jan. 26) will give investors their first glimpse of sentiment. After that, attention shifts to VeriSilicon’s audited 2025 annual report, where details on margins and cash burn will be closely examined.

Stock Market Today

  • Analysts Boost Broadcom Price Targets Despite Stock Dip
    May 20, 2026, 11:22 PM EDT. Broadcom (AVGO) shares fell 6.5% to $411.07 on May 19, retreating from a record high of $439.79 on May 14. Despite this drop, several major analysts raised their price targets. Wells Fargo lifted its target to $545 from $430, TD Cowen to $500 from $405, and UBS to $490 from $475, all maintaining buy ratings. Evercore ISI's Mark Lipacis, a top-ranked analyst, raised his target to $582, citing growing demand for Broadcom's custom AI chips amid shifts in AI workloads. Risks remain from semiconductor market volatility and geopolitical tensions impacting chip deals. Broadcom's strategic moves, including its VMware acquisition and partnerships with Google and Meta for AI-focused chips, position it well in enterprise infrastructure and AI growth.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Goldman Sachs stock slides into Fed week after CEO pay disclosure
Previous Story

Goldman Sachs stock slides into Fed week after CEO pay disclosure

Vallourec’s Delphy hydrogen storage lands Hyvolution award nod as Paris show nears
Next Story

Vallourec’s Delphy hydrogen storage lands Hyvolution award nod as Paris show nears

Go toTop